Roche: FDA approves Rituxan for certain blood cancers.
(CercleFinance.com) - Swiss drugmaker Roche said on Friday that the US Food and Drug Administration (FDA) has approved its Rituxan Hycela immunotherapy for the treatment of certain blood cancers.
The Basel-based firm also disclosed new data from numerous studies ahead of the European Hematology Association (EHA) congress, which kicked off in Madrid yesterday.
Roche said that the presentation confirmed that Venclexta/Venclyxto monotherapy was beneficial for certain patients with high-risk chronic lymphocytic leukaemia, as well as the drug's potential in other hard-to-treat blood cancers.
The company also presented new data reinforcing the clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma.
Furthermore, ahead of the congress of the European Academy of Neurology (EAN), which will start tomorrow in Amsterdam, Roche unveiled new data showing that Ocrevus significantly reduced disease progression in relapsing and primary progressive multiple sclerosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Basel-based firm also disclosed new data from numerous studies ahead of the European Hematology Association (EHA) congress, which kicked off in Madrid yesterday.
Roche said that the presentation confirmed that Venclexta/Venclyxto monotherapy was beneficial for certain patients with high-risk chronic lymphocytic leukaemia, as well as the drug's potential in other hard-to-treat blood cancers.
The company also presented new data reinforcing the clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma.
Furthermore, ahead of the congress of the European Academy of Neurology (EAN), which will start tomorrow in Amsterdam, Roche unveiled new data showing that Ocrevus significantly reduced disease progression in relapsing and primary progressive multiple sclerosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.